Grünenthal announced the acquisition of Mestex through the purchase of all of its shares and outstanding options.
Mestex is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee. The investigational medicine is currently concluding Phase II of clinical development and is about to enter Phase III.
Homburger advises Grünenthal on this matter as to all matters of Swiss law with a team including partner Andreas Müller (Corporate / M&A; Employment and Executive Compensation), counsel Peter Müller (Tax; Employment and Executive Compensation), associate Mirko Stiefel and junior associate Daniel Bötticher (both Corporate / M&A).
Freshfields Bruckhaus Deringer acts as global transaction counsel to Grünenthal.